![](https://kewinc.com/wp-content/uploads/2017/07/headline.png)
WHY COMPREHENSIVE GENOMIC PROFILING?
Single gene tests target single hotspot events, like BRAF V600E mutation, or involvement in a translocation with often undetermined partner. Unless the specific gene that causes cancer is known, patients usually need to get several single gene tests in order to find therapeutic options.
Hot-spot cancer panels target regions of known cancer genes that have been well-characterized as mutational hot spots. Vast majority of hotspot tests use PCR amplicons technology. Amplicon capture based tests are unable to reliably detect deletions, gene amplifications and translocations. Hot-spot analysis misses up to 20% of clinically important mutations in some tumors1. Hot-spots can be extremely sensitive (down to 0.1% at >2000x sequence coverage), however clinical significance of low-level mutations is uncertain.
Unlike single-gene and hot-spot testing, comprehensive genomic profiling evaluates most cancer-related genes in a single test in the most accurate and cost effective manner.
![](https://kewinc.com/wp-content/uploads/2017/07/Why-CGP.png)
CANCERPLEX sequences the whole coding region of genes, detecting less common alterations of the direct drug targets. CancerPlex matches all functional domains of proteins involved in “drugable” pathways – indirect targets, which dramatically increases the rate of matching patient to therapeutic options. CANCERPLEX is one of the best-in-class sequencing platform with comprehensive gene coverage and high clinical actionability.
![](https://kewinc.com/wp-content/uploads/2017/07/headline.png)
- Sorich M, Wiese M, Rowland A, Kichenadasse G, McKinnon R, Karapetis C. Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized, Controlled Trials. Ann Oncol. 2015; 26(1): 13-21.